New EU subcutaneous Orencia approval to help BMS better demonstrate value to payers?
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has approved a subcutaneous version of Bristol Myers Squibb's rheumatoid arthritis drug Orencia (abatacept), which could save some hospitals money because it allows for self-administration. But despite the potential savings, it is unclear whether the new formulation will convince payers to choose the product.